{"id":"bms-986231","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BMS-986231 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing T cell activation and anti-tumor activity.","oneSentence":"BMS-986231 is an anti-PD-1 monoclonal antibody.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:20.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT03730961","phase":"PHASE2","title":"An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-01-17","conditions":"Cardiac Failure, Myocardial Failure, Congestive Heart Failure","enrollment":23},{"nctId":"NCT03016325","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-13","conditions":"Heart Failure","enrollment":329},{"nctId":"NCT03515980","phase":"PHASE1","title":"An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-25","conditions":"Liver Dysfunction, Liver Insufficiency, Hepatic Failure","enrollment":76},{"nctId":"NCT03357731","phase":"PHASE2","title":"A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-30","conditions":"Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction","enrollment":49},{"nctId":"NCT03891108","phase":"PHASE1","title":"A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-02-28","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT03332186","phase":"PHASE1","title":"A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-15","conditions":"Myocardial Failure, Cardiac Failure, Congestive Heart Failure","enrollment":48},{"nctId":"NCT02157506","phase":"PHASE2","title":"A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-30","conditions":"Heart Failure, Decompensated Heart Failure, Acute Heart Failure","enrollment":70},{"nctId":"NCT03210909","phase":"PHASE1","title":"Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-06-22","conditions":"Heart Decompensation, Acute","enrollment":5},{"nctId":"NCT02932969","phase":"PHASE1","title":"Study With Healthy Japanese and Non-Asian Participants With BMS-986231","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-10-04","conditions":"Heart Decompensation, Acute","enrollment":56},{"nctId":"NCT02819271","phase":"PHASE1","title":"A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Heart Failure","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BMS-986231","genericName":"BMS-986231","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986231 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}